文献速递神经核医学肿瘤 PET/CT

垂体肿瘤的分子影像学

Molecular Imaging of Pituitary Tumors.
PubMed 文献 · Semin Nucl Med · 2023-03-23

垂体肿瘤虽多为良性腺瘤,但因局部压迫和激素分泌异常可致显著病残甚至超额死亡。MRI在治疗规划中居核心地位,但治疗后解剖结构改变时难以可靠识别病灶。分子影像尤其是PET(空间分辨率和灵敏度优于SPECT)可精准定位活性病灶,靶向生长抑素受体、多巴胺受体或氨基酸摄取的放射性配体正逐步进入常规临床实践。

要点

  • 垂体肿瘤可因局部压迫(如视力丧失、垂体功能减退)和激素分泌异常(如肢端肥大症、库欣病)导致显著病残甚至超额死亡。
  • MRI是多数患者治疗规划的核心手段,但治疗后解剖重塑导致解剖外观不确定时,不能始终可靠识别原发或复发灶部位。
  • 分子影像中PET因空间分辨率和灵敏度优于SPECT而为首选,靶向生长抑素受体、多巴胺受体或氨基酸摄取的配体正开始用于常规临床实践。

核心结论

  • 分子影像有望成为改变游戏规则的手段,可精准定位活性病灶,使患者在接受靶向干预的同时免于昂贵的终身药物治疗。
  • 分子影像在垂体肿瘤管理中可能将继续获得越来越多应用,正如其已在内分泌疾病中所实现的那样。

研究设计与样本

  • 本文为综述,围绕垂体及鞍旁影像的分子影像学应用进行论述,比较了PET与SPECT并汇总了不同垂体腺瘤亚型中研究的PET放射性配体。

主要发现

  • 18F-氟脱氧葡萄糖(18F-FDG)虽广泛可及,但肿瘤摄取异质性显著,限制了其应用。
  • 靶向垂体腺瘤生物学相关特定分子通路(如生长抑素受体或 dopamine 受体表达、氨基酸摄取)的配体日益受到青睐,并开始应用于常规临床实践。
  • 已提出通过比较不同放射性示踪剂获得的图像来区分腺瘤组织与正常腺体,以及通过减影成像提高对可疑异常灶确为病理性的信心等新方法。

临床怎么用

  • 在MRI因治疗后重塑导致解剖外观不确定、不能可靠识别原发或复发灶部位时,分子影像可精准定位活性病灶并支持安全有效的靶向干预。
  • 靶向生长抑素受体、多巴胺受体或氨基酸摄取的PET配体正开始进入常规临床实践。

局限性

  • 18F-FDG虽广泛可及,但肿瘤摄取异质性显著,限制了其应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumors of the pituitary gland, although mostly benign adenomas, are a cause of significant morbidity and even excess mortality due to local compressive effects (eg visual loss, hypopituitarism) and unregulated hormone secretion (eg acromegaly or Cushing Disease). Surgery, radiotherapy, and medical management (sometimes in combination) may be needed to mitigate the effects of tumor expansion and endocrine dysfunction. Magnetic resonance imaging (MRI) plays a central role in treatment planning for most patients. However, it does not always reliably identify the site(s) of primary or recurrent disease, especially where post-treatment remodeling results in indeterminate anatomical appearances. In these contexts, molecular imaging is a potential game-changer, allowing precise localization of sites of active disease and enabling safe and effective targeted intervention when patients would otherwise be consigned to expensive life-long medication. For pituitary and parasellar imaging, PET is the preferred modality due to its superior spatial resolution and sensitivity compared with SPECT, and an array of PET radioligands have been studied in different pituitary adenoma (PA) subtypes. While 18F-fluorodeoxyglucose (18F-FDG) is widely available, significant heterogeneity in tumoral uptake has limited its use. Instead, ligands targeting specific molecular pathways relevant to PA biology (eg somatostatin or dopamine receptor expression, amino acid uptake) are increasingly preferred and are beginning to find application in routine clinical practice. In addition, novel approaches to distinguish adenomatous tissue from normal gland (eg through comparison of images obtained with different radiotracers) and increase confidence that a suspected abnormal focus is indeed pathological (eg through subtraction imaging) have been proposed. It is likely therefore that molecular imaging will continue to find increasing application in the management of pituitary tumors just as it already does in other endocrine disorders.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gillett D, MacFarlane J, Bashari W, et al. Molecular Imaging of Pituitary Tumors. Semin Nucl Med. 2023. PMID: 36966020. doi:10.1053/j.semnuclmed.2023.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。